Thomas G. Wilson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Thomas G. Wilson has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Shabana Amanda Ali
Henry Ford Health + Michigan State University Health Sciences, Detroit, MI, USA
5 shared publications - Madhu Baghel
Henry Ford Health + Michigan State University Health Sciences, Detroit, MI, USA
4 shared publications Vasilios Moutzouros
Henry Ford Health, Detroit, MI, USA
4 shared publicationsDevin Mendez
Bone and Joint Center, Henry Ford Health + Michigan State University Health Sciences, Detroit, USA
2 shared publicationsIndrani Datta
Center for Bioinformatics, Henry Ford Health + Michigan State University Health Sciences, Detroit, USA
2 shared publicationsJason Davis
Department of Orthopedic Surgery, Henry Ford Health, Detroit
2 shared publications
Latest Publications
- Open Access
Biomarker and therapeutic applications of a novel microRNA in early-stage knee osteoarthritis
Osteoarthritis is a debilitating joint disease with no known cure, underscoring the need for early detection and intervention. Given their potential disease-specificity, novel microRNAs are promising biomarkers and therapeutic targets. Novel microRNAs are identified from sequencing data using bioinformatics analyses. Here we aimed to characterize a novel microRNA (novel_miRNA_2; UCCCUGUUCGGGCGCCACU) in knee osteoarthritis. We show circulating novel_miRNA_2 accurately distinguishes early-stage knee osteoarthritis from both non-osteoarthritis and late-stage knee osteoarthritis. In knee osteoarthritis subchondral bone, novel_miRNA_2 functions as a canonical microRNA, downregulating target genes such as RUNX2 . In male mice, novel_miRNA_2 mimic attenuates knee osteoarthritis when delivery begins in early stages, but not late stages. The decline in novel_miRNA_2 in late-stage knee osteoarthritis may be governed by Hedgehog signaling, which is known to upregulate genes such as RUNX2 and exacerbate osteoarthritis. Our findings suggest endogenous novel_miRNA_2 can be used to detect early-stage knee osteoarthritis when exogenous delivery can mitigate disease.
Open AccessBiomarker and therapeutic applications of a novel microRNA in early-stage knee osteoarthritis
Osteoarthritis is a debilitating joint disease with no known cure, underscoring the need for early detection and intervention. Given their potential disease-specificity, novel microRNAs are promising biomarkers and therapeutic targets. Novel microRNAs are identified from sequencing data using bioinformatics analyses. Here we aimed to characterize a novel microRNA (novel_miRNA_2; UCCCUGUUCGGGCGCCACU) in knee osteoarthritis. We show circulating novel_miRNA_2 accurately distinguishes early-stage knee osteoarthritis from both non-osteoarthritis and late-stage knee osteoarthritis. In knee osteoarthritis subchondral bone, novel_miRNA_2 functions as a canonical microRNA, downregulating target genes such as RUNX2 . In male mice, novel_miRNA_2 mimic attenuates knee osteoarthritis when delivery begins in early stages, but not late stages. The decline in novel_miRNA_2 in late-stage knee osteoarthritis may be governed by Hedgehog signaling, which is known to upregulate genes such as RUNX2 and exacerbate osteoarthritis. Our findings suggest endogenous novel_miRNA_2 can be used to detect early-stage knee osteoarthritis when exogenous delivery can mitigate disease.
- 21 August 2025
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 33 (11) , 1293-1299
Osteoarthritis year in review 2025: Genetics, genomics, and epigenetics
- 21 August 2025
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 33 (11) , 1293-1299
Osteoarthritis year in review 2025: Genetics, genomics, and epigenetics
- Open Access
- 27 February 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-13
Circulating miR-126-3p is a mechanistic biomarker for knee osteoarthritis
Osteoarthritis is a major contributor to pain and disability worldwide, yet there are currently no validated soluble biomarkers or disease-modifying treatments. Given that microRNAs are promising mechanistic biomarkers that can be therapeutically targeted, in this study, we aimed to identify and prioritize reproducible circulating microRNAs associated with radiographic knee osteoarthritis. Across four independent cohorts, we find circulating miR-126-3p is elevated in knee osteoarthritis versus controls. Across six primary human knee osteoarthritis tissues, miR-126-3p is highest in subchondral bone, fat pad and synovium, and lowest in cartilage. Following both intravenous and intra-articular miR-126-3p mimic treatment in a surgical mouse model of knee osteoarthritis, we show reduced disease severity in males. In human knee osteoarthritis biospecimens, miR-126-3p mimic treatment reduces genes and markers associated with angiogenesis, as well as genes linked to osteogenesis, adipogenesis, and synovitis—processes secondary to angiogenesis. Our findings indicate that miR-126-3p is elevated in knee osteoarthritis and mitigates disease severity, supporting its potential as a biomarker and therapeutic target.
- 27 February 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-13
Open AccessCirculating miR-126-3p is a mechanistic biomarker for knee osteoarthritis
Osteoarthritis is a major contributor to pain and disability worldwide, yet there are currently no validated soluble biomarkers or disease-modifying treatments. Given that microRNAs are promising mechanistic biomarkers that can be therapeutically targeted, in this study, we aimed to identify and prioritize reproducible circulating microRNAs associated with radiographic knee osteoarthritis. Across four independent cohorts, we find circulating miR-126-3p is elevated in knee osteoarthritis versus controls. Across six primary human knee osteoarthritis tissues, miR-126-3p is highest in subchondral bone, fat pad and synovium, and lowest in cartilage. Following both intravenous and intra-articular miR-126-3p mimic treatment in a surgical mouse model of knee osteoarthritis, we show reduced disease severity in males. In human knee osteoarthritis biospecimens, miR-126-3p mimic treatment reduces genes and markers associated with angiogenesis, as well as genes linked to osteogenesis, adipogenesis, and synovitis—processes secondary to angiogenesis. Our findings indicate that miR-126-3p is elevated in knee osteoarthritis and mitigates disease severity, supporting its potential as a biomarker and therapeutic target.
- Open Access
Circulating microRNA profiles in early-stage osteoarthritis and rheumatoid arthritis
Background Osteoarthritis (OA) and rheumatoid arthritis (RA) are prevalent forms of arthritis. Early detection of OA and RA is challenging with existing methods, which can delay effective management. MicroRNAs are small molecules that have emerged as promising disease biomarkers with the potential to improve early detection and differentiation of arthritis subtypes. In this study we aimed to identify distinct circulating microRNAs in plasma from individuals with early OA and early RA, using an unbiased microRNA-sequencing approach. Methods Plasma samples were collected from three study groups including: (a) early OA (N=20), individuals with knee OA symptoms and radiographic Kellgren-Lawrence grade 0 or 1; (b) early RA (N=12), treatment-naïve individuals with Results Principal component analyses revealed clustering of early OA versus both early RA and non-OA/RA groups, but not between early RA and non-OA/RA. In early OA, n=170 differentially expressed (DE) microRNAs were identified compared to both early RA and non-OA/RA, while no significant differences were found between early RA and non-OA/RA. Of these DE microRNAs, stepwise filtering and RT-qPCR validation identified dysregulation of six known microRNAs between early OA and early RA. Of these six microRNAs, two were upregulated in early OA, including hsa-miR-16-5p and hsa-miR-29c-3p, and four were upregulated in early RA, including hsa-miR-744-5p, hsa-miR-382-5p, hsa-miR-3074-5p, and hsa-miR-11400. Additionally, one novel microRNA sequence was found to be enriched in early OA and four in early RA. Conclusion We identified a total of six known and five novel circulating microRNAs that differ between early OA and early RA individuals. Validation of these microRNAs in independent cohorts is warranted to establish their biomarker potential for distinguishing individuals with early OA versus early RA.
Open AccessCirculating microRNA profiles in early-stage osteoarthritis and rheumatoid arthritis
Background Osteoarthritis (OA) and rheumatoid arthritis (RA) are prevalent forms of arthritis. Early detection of OA and RA is challenging with existing methods, which can delay effective management. MicroRNAs are small molecules that have emerged as promising disease biomarkers with the potential to improve early detection and differentiation of arthritis subtypes. In this study we aimed to identify distinct circulating microRNAs in plasma from individuals with early OA and early RA, using an unbiased microRNA-sequencing approach. Methods Plasma samples were collected from three study groups including: (a) early OA (N=20), individuals with knee OA symptoms and radiographic Kellgren-Lawrence grade 0 or 1; (b) early RA (N=12), treatment-naïve individuals with Results Principal component analyses revealed clustering of early OA versus both early RA and non-OA/RA groups, but not between early RA and non-OA/RA. In early OA, n=170 differentially expressed (DE) microRNAs were identified compared to both early RA and non-OA/RA, while no significant differences were found between early RA and non-OA/RA. Of these DE microRNAs, stepwise filtering and RT-qPCR validation identified dysregulation of six known microRNAs between early OA and early RA. Of these six microRNAs, two were upregulated in early OA, including hsa-miR-16-5p and hsa-miR-29c-3p, and four were upregulated in early RA, including hsa-miR-744-5p, hsa-miR-382-5p, hsa-miR-3074-5p, and hsa-miR-11400. Additionally, one novel microRNA sequence was found to be enriched in early OA and four in early RA. Conclusion We identified a total of six known and five novel circulating microRNAs that differ between early OA and early RA individuals. Validation of these microRNAs in independent cohorts is warranted to establish their biomarker potential for distinguishing individuals with early OA versus early RA.
- Open Access
Circulating miR-126-3p is a mechanistic biomarker for knee osteoarthritis
As a chronic joint disease, osteoarthritis (OA) is a major contributor to pain and disability worldwide, and yet there are currently no validated soluble biomarkers or disease-modifying treatments. Since microRNAs are promising mechanistic biomarkers that can be therapeutically targeted, we aimed to prioritize reproducible circulating microRNAs in knee OA. We performed secondary analysis on two microRNA-sequencing datasets and found circulating miR-126-3p to be elevated in radiographic knee OA compared to non-OA individuals. This finding was validated in an independent cohort (N=145), where miR-126-3p showed an area under the receiver operating characteristic curve of 0.91 for distinguishing knee OA. Measuring miR-126-3p in six primary human knee OA tissues, subchondral bone, fat pad and synovium exhibited the highest levels, and cartilage the lowest. Following systemic miR-126-3p mimic treatment in a surgical mouse model of knee OA, we found reduced disease severity. Following miR-126-3p mimic treatment in human knee OA tissue explants, we found direct inhibition of genes associated with angiogenesis and indirect inhibition of genes associated with osteogenesis, adipogenesis, and synovitis. These findings suggest miR-126-3p becomes elevated during knee OA and mitigates disease processes to attenuate severity.
Open AccessCirculating miR-126-3p is a mechanistic biomarker for knee osteoarthritis
As a chronic joint disease, osteoarthritis (OA) is a major contributor to pain and disability worldwide, and yet there are currently no validated soluble biomarkers or disease-modifying treatments. Since microRNAs are promising mechanistic biomarkers that can be therapeutically targeted, we aimed to prioritize reproducible circulating microRNAs in knee OA. We performed secondary analysis on two microRNA-sequencing datasets and found circulating miR-126-3p to be elevated in radiographic knee OA compared to non-OA individuals. This finding was validated in an independent cohort (N=145), where miR-126-3p showed an area under the receiver operating characteristic curve of 0.91 for distinguishing knee OA. Measuring miR-126-3p in six primary human knee OA tissues, subchondral bone, fat pad and synovium exhibited the highest levels, and cartilage the lowest. Following systemic miR-126-3p mimic treatment in a surgical mouse model of knee OA, we found reduced disease severity. Following miR-126-3p mimic treatment in human knee OA tissue explants, we found direct inhibition of genes associated with angiogenesis and indirect inhibition of genes associated with osteogenesis, adipogenesis, and synovitis. These findings suggest miR-126-3p becomes elevated during knee OA and mitigates disease processes to attenuate severity.